These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience. Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652 [TBL] [Abstract][Full Text] [Related]
7. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906 [TBL] [Abstract][Full Text] [Related]
8. Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care. Koehne G; Giralt S Curr Opin Oncol; 2012 Nov; 24(6):720-6. PubMed ID: 22960558 [TBL] [Abstract][Full Text] [Related]
9. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Qazilbash MH; Saliba R; De Lima M; Hosing C; Couriel D; Aleman A; Roden L; Champlin R; Giralt SA Cancer; 2006 Mar; 106(5):1084-9. PubMed ID: 16456814 [TBL] [Abstract][Full Text] [Related]
10. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation. Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846 [TBL] [Abstract][Full Text] [Related]
11. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma. El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414 [TBL] [Abstract][Full Text] [Related]
12. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644 [TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Gerull S; Goerner M; Benner A; Hegenbart U; Klein U; Schaefer H; Goldschmidt H; Ho AD Bone Marrow Transplant; 2005 Dec; 36(11):963-9. PubMed ID: 16184182 [TBL] [Abstract][Full Text] [Related]
15. Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. Passera R; Pollichieni S; Brunello L; Patriarca F; Bonifazi F; Montefusco V; Falda M; Montanari M; Guidi S; Giaccone L; Mordini N; Carella AM; Bavaro P; Milone G; Benedetti F; Ciceri F; Scimè R; Benedetti E; Castagna L; Festuccia M; Rambaldi A; Bacigalupo A; Corradini P; Bosi A; Boccadoro M; Bandini G; Fanin R; Bruno B Biol Blood Marrow Transplant; 2013 Jun; 19(6):940-8. PubMed ID: 23538113 [TBL] [Abstract][Full Text] [Related]
16. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940 [TBL] [Abstract][Full Text] [Related]
17. Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation. Hunter HM; Peggs K; Powles R; Rahemtulla A; Mahendra P; Cavenagh J; Littlewood T; Potter M; Hunter A; Pagliuca A; Williams CD; Cook G; Towlson K; Marks David I; Russell NH; Br J Haematol; 2005 Feb; 128(4):496-502. PubMed ID: 15686458 [TBL] [Abstract][Full Text] [Related]
18. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680 [TBL] [Abstract][Full Text] [Related]
19. Non-myeloablative allogeneic peripheral stem cell transplantation for multiple myeloma. Ma SY; Lie AK; Au WY; Chim CS; Kwong YL; Liang R Hong Kong Med J; 2004 Apr; 10(2):77-83. PubMed ID: 15075426 [TBL] [Abstract][Full Text] [Related]
20. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia]. Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]